A Prospective Randomized Double Blind Placebo Controlled Phase II Trial of Intra-coronary Infusion of AMR-001, a Bone Marrow Derived Autologous CD34+ Selected Cell Product, in Patients With Acute Myocardial Infarction

Trial Profile

A Prospective Randomized Double Blind Placebo Controlled Phase II Trial of Intra-coronary Infusion of AMR-001, a Bone Marrow Derived Autologous CD34+ Selected Cell Product, in Patients With Acute Myocardial Infarction

Completed
Phase of Trial: Phase II

Latest Information Update: 02 May 2016

At a glance

  • Drugs NBS 10 (Primary)
  • Indications Myocardial infarction
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PreSERVE-AMI
  • Sponsors Amorcyte; Caladrius Biosciences
  • Most Recent Events

    • 26 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 15 Mar 2016 According to a Caladrius Biosciences media release, the company announced the decision to conclude the study after two year rather than three year follow-up as the important data has been realized and to avoid additional material expenses.
    • 02 Jun 2015 Results published in the American College of Cardiology 64th Annual Scientific Session and Expo, as per NeoStem media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top